{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/65359c4d48cdf000129a1742?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"68. ESMO 2023 - Central Nervous System Tumors","description":"<p>Another year, another international oncology conference in a beautiful European locale. In 2023, the world's oncology community has descended on the Spanish capital Madrid to discuss the latest and greatest scientific developments in Medical Oncology. And as always seems to be the case, Michael and Josh remain at home listening to this avalanche of information virtually. Despite a distinct lack of sun and Español, our intrepid duo will continue a grand tradition that dates back to 2022: bringing some of the best highlights from Madrid directly to your ears across a series of episodes to be released this week.</p><p><br></p><p>In the first episode of this series, Josh and Michael start in the most difficult of tumour streams: CNS oncology, an area where outcomes continue to be incredibly poor. ESMO 2023 brought some very interesting early-phase trials and no small amount of controversy, but that silver bullet unfortunately continues to elude oncology's brightest minds. Listen on to find out more.</p><p><br></p><p>Studies discussed in this episode. Subscription may be required</p><ul><li>REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients. <a href=\"https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637999\" rel=\"noopener noreferrer\" target=\"_blank\">https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637999</a></li><li>Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial <a href=\"https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637931\" rel=\"noopener noreferrer\" target=\"_blank\">https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637931</a></li><li>A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma <a href=\"https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637997\" rel=\"noopener noreferrer\" target=\"_blank\">https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637997</a> </li></ul><p><br></p><p>For more episodes, resources and blog posts, visit <a href=\"https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>www.inquisitiveonc.com</strong></a></p><p>Please find us on Twitter @InquisitiveOnc!</p><p>If you want us to look at a specific trial or subject, email us at<strong> </strong><a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>inquisitiveonc@gmail.com</strong></a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/</p><p><br></p><p><strong>Disclaimer:</strong> This podcast is for educational purposes only. If you are unwell, seek medical advice.</p>","author_name":"Michael Fernando and Josh Hurwitz"}